NEWS
Discover how Chroma is expanding our impact.
IN THE NEWS
Jeff Marrazzo has found a buzzy new biotech cause to champion. And once again, he’s all in
PRESS RELEASES
Chroma Medicine Welcomes Spark Therapeutics Co-Founder and Former Founding CEO Jeff Marrazzo to Board of Directors
Cambridge, MA, October 4, 2022 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the addition of Jeff Marrazzo, co-founder and former founding CEO of Spark Therapeutics, to its Board of Directors. “Jeff’s leadership at Spark yielded the first-ever approved gene therapy, and we are thrilled to bring his expertise to the Chroma Board,” said Catherine Stehman-Breen, M.D., CEO of Chroma. “He is a proven company builder who has successfully led the advancement of novel genomic medicines to patients. His unique perspective as a gene therapy pioneer will be instrumental as we reimagine…
PRESS RELEASES
Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy
Cambridge, MA, September 20, 2022 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the formation of a Scientific Advisory Board (SAB) comprising renowned leaders in epigenetics, cell and gene therapy, and synthetic biology: Bradley Bernstein, M.D., Ph.D., Paula Cannon, Ph.D., Howard Chang, M.D., Ph.D., and Ahmad (Mo) Khalil, Ph.D. The SAB members will provide key input to Chroma as the company advances its programs addressing a wide range of diseases. “Each of these distinguished experts will be instrumental as we unlock the potential of epigenetic editing therapeutics,” said Catherine Stehman-Breen, M.D., Chief…